Puricore Share Discussion Threads

[chrisis33] 11/9/2013 17:50

Thanks for the link. I don't have access to the broker note I'm afraid. Nice 40k buy to end the day.

[0rb1t] 11/9/2013 14:06

Have a look at the presentation from the last results:



It looks like the growth will come from globalising their products, selling the solutions ready-made and also moving into similar markets (ie agriculture and husbandry). They have lots of shared agreements including with Oxford University.

I guess the IP comes from the machines that have been created for producing hypochlorous acid and the sterilisation equipment.

Does anyone have access to the Peel Hunt broker note?

[eezymunny] 11/9/2013 11:59

I'm intrigued by the big director buy but don't know much about this lot.

The main revenues currently come from patented production methods of producing hypochlorous acid...but they aren't the only ones who do this:

thepoultrysite.com/poultrynews/23963/system-produces-hypochlorous-acid-on-demand

Terriss Consolidated Industries mentioned, apparently something similar.

So what's the big deal here? Which of the products justifies this director confidence? Just more hypochlorous acid product wins and a move into profitability or is there some knock-out IP here in the Activita stuff? or something else?

Thoughts?

[chrisis33] 10/9/2013 15:56

Director buy ... that's all as far as I can see. Been in here before, and bought today mostly due to the potential in the agriculture sector.

[alexkb] 09/9/2013 22:58

ive been watching this get higher recently. no news too. anything im missing.

[it_trader] 06/9/2013 13:03

Wow. Big non-exec director buy £256,500.

[mathewawood] 27/6/2013 11:23

At last Peel Hunt have finally put out their earnings forecasts!

I've been sending them e-mails basically telling them that the information is vital for an average investor to make the decision whether or not to invest in the company. And that along with a current buy/sell spread of 10% on the share price, the investment potential is being strangled to death by the brokers it actually pays to make investing in the company easier!
They got back to me saying it was regulations they couldn't publish. I said what regulations? ...And now this. Ha.

There earnings are roughly similar to mine. Break even 2013 and 100% EPS growth from then on. Hence stonking buy material. Can't say I've ever seen a price target 2.7X the share price

Last train departing before it multi-bags!

[it_trader] 25/6/2013 10:20

Hopefully we'll now get some interest and a smaller spread. I'm sure that's putting a lot of people off.

[bubbleandleek] 25/6/2013 10:05

lovely big BUY note out from Peel Hunt yesterday - 107p px tgt

[mathewawood] 20/6/2013 08:46

Thats the second big contract win in 2 months. This company has finally moved into top gear. Now certain to move into profit this year and with huge growth potential. Mkt cap of £21M and sales expected to be $63M+ with margins improving year on year. Last chance to enter before it multi-bags.

[stylesip] 20/6/2013 07:07

News Alert for Puricore .RNS Number : 4438HPuriCore Plc20 June 2013 ?PuriCore plc ("PuriCore" or the "Company")20 June 2013 PuriCore Signs Major US Deal $13.5 Million Agreement Launches Strategically Important ProduceFresh Bottled Concentrate PuriCore (LSE: PURI), the global company focused on advancing human health through the control of infectious pathogens, today announces it has signed a sales agreement for its new ProduceFresh™ bottled concentrate valued at an estimated $13.5 million with a top-three US supermarket retailer. Under the terms of the agreement, the retailer will use ProduceFresh across all of its stores for a committed term of approximately four years commencing in Q3 2013. PuriCore expects this revenue will be booked in the Company's financial accounts from 2013 through to 2017. ProduceFresh is the most recent product offering in the PuriCore supermarket retail portfolio, which includes the Sterilox® Fresh System and FloraFresh® bottled concentrate. Like the Sterilox Fresh System, new ProduceFresh bottled concentrate reduces the risk of the transmission of foodborne illnesses in retail supermarkets and reduces inventory shrink. This new offering provides retail customers with greater choice according to their business model, either on-site generation of Sterilox Fresh solution or delivery of ProduceFresh bottled concentrate solution for on-site dilution. This additional bottled product provides PuriCore with a long-term recurring revenue stream and reduces the costs of manufacturing, installation, and servicing. Michael Ashton, Executive Chairman, said:"ProduceFresh is an important expansion to our product portfolio as this sales agreement clearly demonstrates, offering customers a choice that best addresses their particular business needs. The ProduceFresh offering also enables us to increase our market reach to retail customers and foodservice operators whose businesses are better suited to a bottled product."

[bean02] 17/5/2013 12:15

Coming back now...:)

[bean02] 17/5/2013 08:57

Bargain buy for me:)

[stylesip] 17/5/2013 07:00

PuriCore plc("PuriCore" or the "Company")17 May 2013 Interim Management StatementBalance sheet significantly improved PuriCore (LSE: PURI), the water-based clean technology company, today announces its Interim Management Statement for the period from 1 January 2013 to 17 May 2013 (which incorporates information in relation to the financial performance of the business for the first quarter being from 1 January 2013 to 31 March 2013). Q1 Financial Highlights (unaudited)· Group revenue down 23.7% (23.2% at constant currency) to $10.9m (Q1 2012: $14.3m)§ Supermarket Retail revenue down 51.0% to $3.6m (Q1 2012: $7.4m)§ Endoscopy revenue down 4.9% (3.9% at constant currency) to $6.2m (Q1 2012: $6.6m)§ Wound Care revenue up 188.5% to $1.1m (Q1 2012: $0.4m)· EBITDA* profitable in Endoscopy and Wound Care businesses· Gross profit margin improved by 4.6 percentage points· Gross cash of $4.3m at 31 March 2013 * Earnings before interest, tax, depreciation, and amortisation. Business and Operational Highlights· Strengthened the balance sheet§ Converted 95% of the £7.95m of Convertible Loan Notes§ Raised approximately £2.3m (before expenses) in a placingFood & Agriculture· Signed a $14m Sterilox Fresh agreement with a top-five US supermarket retailerHealth Sciences· Received US FDA regulatory clearance for Vashe Skin and Wound Hydrogel formulation itch related to atopic dermatitis· Formed marketing partnership with Onset Dermatologics for new Vashe-based dermatologic hydrogel products· Formed marketing partnership with SteadMed Medical in April for marketing of Vashe Wound Therapy in the US, Canada, and Mexico Michael Ashton, Executive Chairman, said:"We significantly improved our balance sheet in the quarter. Comparative revenue results, however, were affected by very high installations of Sterilox Fresh Systems during Q1 2012 as well as the receipt of a $14 million Sterilox Fresh contract that was not signed and therefore not delivering revenue until Q2 2013. This agreement and other forthcoming orders in the Supermarket Retail business plus our expansion into the floral departments will continue to drive revenues in the Supermarket Retail segment for the full year. With these sales coupled with our recently signed marketing partnerships in the Wound Care and Dermatology therapeutic areas and an increasing revenue stream from our Endoscopy business, the Directors remain confident in the prospects for the Company going forward." Business ReportDuring the period, the Company significantly strengthened its balance sheet. As announced in December 2012 and approved by shareholders in January, the Company restructured 95.28% of the £7.95 million of Convertible Loan Notes, which mature on 31 December 2013. In addition, the Company completed a placing, announced in December 2012 and approved by shareholders in January, raising approximately £2.3 million in new shares (before expenses) at a price of 43 pence per Ordinary Share. Revenue for the Company decreased 23.7% to $10.9 million (23.2% at constant currency) in the first quarter of 2013 (Q1 2012: $14.3 million). This variance primarily was due to timing of orders in the Supermarket Retail business. Gross profit margin for the Company improved by 4.6 percentage points due to strong results in Wound Care and improving margins in Endoscopy. The Endoscopy and Wound Care businesses were EBITDA profitable in the period. Cash and cash equivalents were $4.3 million as at 31 March 2013. Food & AgricultureIn the Supermarket Retail business, revenue decreased 51% to $3.6 million (Q1 2012: $7.4 million) as expected as the Company prepared to commence installing in Q2 2013 Sterilox Fresh Systems as part of the $14 million agreement with a top-five US supermarket retailer. Under the terms of the agreement, the retailer will broadly implement Sterilox Fresh across its enterprise and has agreed to a six-year warranty agreement. Revenue will be recognised on the agreement beginning in Q2 2013, and the Company expects the majority of the system revenue will be recorded in the 2013 financial accounts. The remaining revenue will be recognised over the term of the warranty. Health SciencesIn the Endoscopy business, revenue decreased 4.9% (3.9% at constant currency) to $6.2 million (Q1 2012: $6.6 million) whilst the business remained EBITDA profitable for the quarter. The Wound Care business was EBITDA profitable with revenue increasing 188.5% to $1.1 million (Q1 2012: $0.4 million). In February, PuriCore announced that it had received US FDA regulatory clearance for Vashe Skin and Wound Hydrogel formulation for the management and relief of pain, burning, and itching experienced with various dermatoses including atopic dermatitis. The clearance was a key milestone in PuriCore's partnership with Onset Dermatologics, a leader in the development and commercialisation of prescription dermatology products, for the sale of Vashe-based dermatology products, which was announced in March. The agreement includes upfront payments and double-digit royalty payments on future sales of Aurstat Anti-Itch Hydrogel and Aurstat Kit. Onset Dermatologics commenced marketing and distributing this new Vashe-based formulation as Aurstat Anti-Itch Hydrogel and as a component of Aurstat Kit exclusively in the US. All intellectual property related to the Vashe hydrogel formulation remains with PuriCore. In April, PuriCore announced a marketing partnership with SteadMed Medical, a leading marketer of acute and chronic wound care products, to commercialise Vashe Wound Therapy in the US, Canada, and Mexico. Vashe will be an integral part of the SteadMed comprehensive protocol of care for acute and chronic wounds and burns, targeting wound care centres, hospitals, and home health agencies. This agreement will expand marketing reach for the Vashe product through SteadMed's experienced sales, marketing, and clinical teams. Under the terms of the multi-year agreement, PuriCore received an upfront payment of $500,000 and will receive royalties in the high teens based on sales volumes. All intellectual property related to Vashe remains with PuriCore. This information is provided by RNSThe company news service from the London Stock Exchange END IMSARMFTMBIBMAJ

[stylesip] 30/4/2013 08:06

Good to see positive results "In 2012, PuriCore grew revenue, improved gross profit margin, and generated positive cash flow"Recurring revenue streams, large contracts.. Interesting times ahead for this one..

[danwaits] 08/4/2013 09:42

Good news today with the bulk of the money, I presume, being provided upfront to cover the costs of installing units in each store.
Does anyone know why this technology is only sold in N. America, whilst the endoscopy cleaning is exclusive to the UK?

[euclid5] 14/2/2013 09:26

can anyone post the recent broker note on thos co please - as I can't see one on their website

great news today considering the mkt cap

[eric76] 14/2/2013 07:41

Another positive rns, this time FDA approval for entry into a $30B US market.
This little co. seems to be making some quite interesting moves yet remains unloved?

[ian 50] 12/11/2012 20:36

Sold awhile ago will buy later falls look inevitable looking at ma

[blueskyventurer] 16/10/2012 13:03

Good,

Looks like a very high potential business, With only there current business,if agri-business this could a multi-bagger ?